Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
暂无分享,去创建一个
Marc P. Bonaca | Deepak L. Bhatt | M. Sabatine | E. Braunwald | Seung‐Jung Park | L. Mauri | A. Lincoff | M. Valgimigli | G. Montalescot | J. Collet | D. Kereiakes | J. Udell | F. Costa | Cheol-Whan Lee
[1] Á. Avezum,et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, JAMA.
[2] Deepak L. Bhatt,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.
[3] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[4] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[5] Deepak L. Bhatt,et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. , 2015, Journal of the American College of Cardiology.
[6] J. Udell. LONG-TERM DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PREVIOUS ACUTE CORONARY SYNDROME: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS , 2015 .
[7] J. Wójcik,et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. , 2015, Journal of the American College of Cardiology.
[8] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[9] Y. Jang,et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.
[10] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[11] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[12] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[13] Á. Avezum,et al. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. , 2015, The American journal of medicine.
[14] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[15] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[16] M. Valgimigli,et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. , 2015, The New England journal of medicine.
[17] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[18] E. Antman,et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.
[19] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[20] T. Jernberg,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.
[21] S. Yusuf,et al. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes , 2003, Circulation.
[22] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[23] V. Menon,et al. Faculty Opinions recommendation of 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013 .
[24] L. Mauri,et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis , 2015, The Lancet.
[25] P. Serruys,et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. , 2009, JACC. Cardiovascular interventions.
[26] Samin K. Sharma,et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.
[27] J. Ioannidis,et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.
[28] M. Valgimigli,et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) t , 2015, European heart journal.
[29] Deepak L. Bhatt,et al. Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes , 2014, Circulation research.
[30] M. Jeong,et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.
[31] J. D. de Lemos,et al. Clinical trial participation after myocardial infarction in a national cardiovascular data registry. , 2014, JAMA.
[32] Antonio Colombo,et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.
[33] Á. Avezum,et al. A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .
[34] J. Schapiro,et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.
[35] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[36] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[37] A. Rabinstein. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial , 2008 .
[38] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[39] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[40] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[41] F. Neumann,et al. Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.
[42] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[43] Fernando Mancha,et al. Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention , 2012, Heart.
[44] Deepak L. Bhatt,et al. Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .
[45] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[46] B. Gersh. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis , 2008 .
[47] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[48] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[49] J. Marchesini,et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.
[50] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[51] E. Vicaut,et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.
[52] F. Van de Werf,et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.
[53] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[54] Deepak L. Bhatt,et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.
[55] Giuseppe Biondi-Zoccai,et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.
[56] Walter Desmet,et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.
[57] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[58] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[59] M. Zwahlen,et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. , 2008, Journal of the American College of Cardiology.
[60] Volkmar Falk,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.
[61] L Roy,et al. Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.
[62] W. Ahmad. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .
[63] J. Ambrose. Faculty Opinions recommendation of 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[64] A. Jacobs,et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. , 2015, Journal of the American College of Cardiology.
[65] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[66] Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2016, British Medical Journal.